

Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

COMPLETION OF TRANSACTION

References are made to the announcements of Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”) dated 17 October 2025, 31 October 2025, 5 January 2026 and 12 February 2026, and the circular of the Company dated 26 January 2026 (the “**Circular**”) in relation to, among other things, the share issue and sale and purchase of assets agreement and the supplemental agreement thereto (collectively, the “**Sale and Purchase Agreement**”) entered into among the Company, Weihai Shengxi Enterprise Management Consulting Center (Limited Partnership)* (威海盛熙企業管理諮詢中心(有限合夥)), Weihai Ruiming Enterprise Management Consulting Partnership (Limited Partnership)* (威海瑞明企業管理諮詢合夥企業(有限合夥)) (collectively, the “**WEGO Prefills Shareholders**”) and Shandong Weigao Blood Purification Products Co., Ltd.* (山東威高血液淨化製品股份有限公司) (“**Weigao Blood Purification**”), pursuant to which Weigao Blood Purification would issue the Consideration Shares (the “**Consideration Share Issue**”) to each of the WEGO Prefills Shareholders to acquire 100% equity interest in WEGO Prefills Pharmaceutical Packaging Co., Ltd.* (山東威高普瑞醫藥包裝有限公司) (“**WEGO Prefills**”) (the “**Transaction**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Circular.

COMPLETION OF THE TRANSACTION

The Board is pleased to announce that all conditions precedent under the Sale and Purchase Agreement have been fulfilled and the transfer of the equity interest in WEGO Prefills and the Consideration Share Issue have both been completed.

Pursuant to the terms of the Sale and Purchase Agreement, as Weigao Blood Purification made a dividend distribution following the signing of the Sale and Purchase Agreement and up to the Completion Date of Issuance, the price of Consideration Shares was adjusted from RMB31.29 per share to RMB30.72 per share, and the total number of Consideration Shares issued was adjusted from 271,997,882 shares to 277,044,717 shares. Weigao Blood Purification has completed the allotment and issue of all the Consideration Shares to each of the WEGO Prefills Shareholders as well as the relevant share issuance and shareholder registration procedures.

Upon Completion, the Group (including the Company and Weihai Ruiming) hold a total of 364,208,053 shares in Weigao Blood Purification, representing approximately 52.42% of the issued share capital of Weigao Blood Purification as at the date of this announcement. Weigao Blood Purification has become a subsidiary of the Company, and its financial results and financial position have been consolidated into the financial statements of the Group. WEGO Prefills has become a wholly-owned subsidiary of Weigao Blood Purification and it will continue to be consolidated into the financial statements of the Group.

The Company believes that the Transaction has expanded the Group's medical device business footprint. Going forward, through further product development cooperation between WEGO Prefills and Weigao Blood Purification, the Group will be able to fully leverage the business synergy between the two companies, further expand its business and profitability, and thereby bring positive impact to the Company and its shareholders.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

25 September 2026
Weihai, Shandong, the PRC

As at the date of this announcement, the Board comprises:

Mr. Long Jing (*Executive Director*)

Mr. Cong Rinan (*Executive Director*)

Mr. Lu Junqiang (*Executive Director*)

Mr. Wang Daoming (*Executive Director*)

Mr. Chen Lin (*Non-executive Director*)

Mr. Tang Zhengpeng (*Non-executive Director*)

Mr. Li Guohui (*Independent Non-executive Director*)

Mrs. Meng Hong (*Independent Non-executive Director*)

Mr. Li Qiang (*Independent Non-executive Director*)

Mr. Sun Heng (*Independent Non-executive Director*)

* *For identification purpose only*